INVESTOR RELATIONS

      Welcome to the Oblique Therapeutics Investor Relations page.

      On this section you can find documents, and other information regarding Oblique Therapeutics.
      Oblique Therapeutics AB is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and aggressive metastatic cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.
      Please do not hesitate to contact us to learn more about our research and technology or to discuss potential collaborations and partnerships. We look forward to hearing from you.

      Contact us directly

      Owe Orwar

      CEO

      +46(0)705-202 217

      owe@obliquet.com

      Daniel Johnsson

      Chairman of the Board

      +46(0) 000-000 000

      e-postadress